ALKS
VENTE TOTALE: 44 472 titres (~2 239 076,26 $ US)
- Insiders
- snyderman nancy lynn MD
- Total bought
- —
- Total sold
- $2,239,076
- Last activity
- 2026-08-03
- Last synced
-
2026-08-09 12:58:10
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-04
ALKS presents a strong financial foundation — high liquidity, minimal debt, and solid cash flow generation — but the event-driven picture is decisively bearish: a significant insider sale (~$2.24M, zero buys)…
The first sentence of the analysis written for ALKS on 2026-08-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | |
| Ebit Margin | 20.6% | 29.9% | 26.7% | -1.6% | 8.4% | |
| Ebitda Margin | 22.4% | 31.8% | 31.2% | 5.4% | 15.1% | |
| Operating Profit Margin | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | |
| Pretax Profit Margin | 19.7% | 28.5% | 25.3% | -2.8% | 7.5% | |
| Continuous Operations Profit Margin | 16.4% | 23.9% | 31.2% | -3.0% | 6.5% | |
| Net Profit Margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | |
| Bottom Line Profit Margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | |
| Current Ratio | 3.550 | 3.042 | 2.856 | 2.271 | 2.254 | |
| Quick Ratio | 3.188 | 2.649 | 2.497 | 1.906 | 1.935 | |
| Solvency Ratio | 0.378 | 0.670 | 0.461 | -0.087 | 0.033 | |
| Cash Ratio | 2.061 | 0.626 | 0.879 | 0.588 | 0.716 | |
| Price To Earnings Ratio | 19.034 | 12.955 | 12.963 | -26.938 | -77.533 | |
| Price To Earnings Growth Ratio | -0.563 | 3.465 | -0.040 | -0.121 | 1.357 | |
| Forward Price To Earnings Growth Ratio | -0.563 | 3.465 | -0.040 | -0.121 | 1.357 | |
| Price To Earnings Diluted Ratio | 19.566 | 13.253 | 13.210 | -26.938 | -77.533 | |
| Price To Earnings Diluted Growth Ratio | -0.574 | 3.976 | -0.042 | -0.121 | 1.357 | |
| Price To Book Ratio | 2.533 | 3.247 | 3.834 | 4.099 | 3.365 | |
| Price To Sales Ratio | 3.122 | 3.054 | 2.772 | 3.848 | 3.189 | |
| Price To Free Cash Flow Ratio | 9.594 | 11.726 | 13.051 | -248.596 | 51.496 | |
| Price To Operating Cash Flow Ratio | 8.849 | 10.832 | 11.489 | 203.316 | 36.804 | |
| Debt To Assets Ratio | 0.028 | 0.037 | 0.174 | 0.193 | 0.206 | |
| Debt To Equity Ratio | 0.038 | 0.052 | 0.309 | 0.364 | 0.374 | |
| Debt To Capital Ratio | 0.037 | 0.049 | 0.236 | 0.267 | 0.272 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.193 | 0.218 | 0.208 | |
| Financial Leverage Ratio | 1.391 | 1.403 | 1.776 | 1.882 | 1.820 | |
| Working Capital Turnover Ratio | 1.264 | 1.626 | 2.082 | 1.817 | 1.858 | |
| Operating Cash Flow Ratio | 0.958 | 0.944 | 0.772 | 0.042 | 0.216 | |
| Operating Cash Flow Sales Ratio | 0.353 | 0.282 | 0.241 | 0.019 | 0.087 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.922 | 0.924 | 0.880 | -0.818 | 0.715 | |
| Debt Service Coverage Ratio | 14.777 | 18.746 | 23.706 | 3.600 | 11.694 | |
| Interest Coverage Ratio | 20.686 | 18.630 | 17.980 | -0.467 | 8.713 | |
| Short Term Operating Cash Flow Coverage Ratio | 77.194 | 0.000 | 133.784 | 7.015 | 33.905 | |
| Operating Cash Flow Coverage Ratio | 7.439 | 5.813 | 1.078 | 0.055 | 0.244 | |
| Capital Expenditure Coverage Ratio | 12.884 | 13.114 | 8.353 | 0.550 | 3.505 | |
| Dividend Paid And Capex Coverage Ratio | 12.884 | 13.114 | 8.353 | 0.550 | 3.505 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 10.755 | 9.176 | 8.712 | 73.034 | 21.521 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 86.7% | ▲2.4% | ▲2.8% |
| Ebit Margin | 20.6% | ▼-9.4% | ▲3.8% |
| Ebitda Margin | 22.4% | ▼-9.3% | ▲1.2% |
| Operating Profit Margin | 17.2% | ▼-9.8% | ▲1.8% |
| Pretax Profit Margin | 19.8% | ▼-8.7% | ▲4.1% |
| Continuous Operations Profit Margin | 16.4% | ▼-7.5% | ▲1.4% |
| Net Profit Margin | 16.4% | ▼-7.2% | ▲7.8% |
| Bottom Line Profit Margin | 16.4% | ▼-7.2% | ▲7.8% |
| Current Ratio | 3.550 | ▲0.507 | ▲0.755 |
| Quick Ratio | 3.188 | ▲0.539 | ▲0.753 |
| Solvency Ratio | 0.378 | ▼-0.292 | ▲0.087 |
| Cash Ratio | 2.061 | ▲1.435 | ▲1.087 |
| Price To Earnings Ratio | 19.034 | ▲6.079 | ▲30.938 |
| Price To Earnings Growth Ratio | -0.563 | ▼-4.029 | ▼-1.383 |
| Forward Price To Earnings Growth Ratio | -0.563 | ▼-4.029 | ▼-1.383 |
| Price To Earnings Diluted Ratio | 19.566 | ▲6.313 | ▲31.255 |
| Price To Earnings Diluted Growth Ratio | -0.574 | ▼-4.550 | ▼-1.493 |
| Price To Book Ratio | 2.533 | ▼-0.714 | ▼-0.882 |
| Price To Sales Ratio | 3.122 | ▲0.069 | ▼-0.075 |
| Price To Free Cash Flow Ratio | 9.594 | ▼-2.132 | ▲42.140 |
| Price To Operating Cash Flow Ratio | 8.850 | ▼-1.983 | ▼-45.409 |
| Debt To Assets Ratio | 0.028 | ▼-0.009 | ▼-0.100 |
| Debt To Equity Ratio | 0.038 | ▼-0.013 | ▼-0.189 |
| Debt To Capital Ratio | 0.037 | ▼-0.012 | ▼-0.135 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.124 |
| Financial Leverage Ratio | 1.391 | ▼-0.012 | ▼-0.264 |
| Working Capital Turnover Ratio | 1.264 | ▼-0.363 | ▼-0.466 |
| Operating Cash Flow Ratio | 0.958 | ▲0.014 | ▲0.372 |
| Operating Cash Flow Sales Ratio | 0.353 | ▲0.071 | ▲0.157 |
| Free Cash Flow Operating Cash Flow Ratio | 0.922 | ▼-0.001 | ▲0.398 |
| Debt Service Coverage Ratio | 14.777 | ▼-3.969 | ▲0.273 |
| Interest Coverage Ratio | 20.686 | ▲2.055 | ▲7.577 |
| Short Term Operating Cash Flow Coverage Ratio | 77.195 | ▲77.195 | ▲26.815 |
| Operating Cash Flow Coverage Ratio | 7.439 | ▲1.626 | ▲4.513 |
| Capital Expenditure Coverage Ratio | 12.884 | ▼-0.231 | ▲5.202 |
| Dividend Paid And Capex Coverage Ratio | 12.884 | ▼-0.231 | ▲5.202 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 10.755 | ▲1.578 | ▼-13.885 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.61B | $4.76B | $4.61B | $4.28B | $3.74B | |
| Enterprise value | $3.56B | $4.54B | $4.53B | $4.37B | $3.82B | |
| EV / Sales | 2.41x | 2.92x | 2.72x | 3.93x | 3.26x | |
| EV / Op. cash flow | 6.83x | 10.34x | 11.28x | 207.45x | 37.58x | |
| EV / Free cash flow | 7.41x | 11.20x | 12.81x | -253.65x | 52.58x | |
| EV / EBITDA | 10.76x | 9.18x | 8.71x | 73.03x | 21.52x | |
| Net debt / EBITDA | -3.17x | -0.44x | -0.16x | 1.46x | 0.44x | |
| Current ratio | 3.55x | 3.04x | 2.86x | 2.27x | 2.25x | |
| Income quality | 2.15x | 1.20x | 1.13x | -0.13x | -2.11x | |
| Graham number | $19 | $21 | $19 | — | — | |
| Graham net-net | $6 | $3 | $1 | $0 | -$0 | |
| Tax burden | 82.9% | 82.7% | 84.4% | 508.4% | -54.9% | |
| Interest burden | 96.0% | 95.2% | 94.8% | 172.1% | 88.7% | |
| Working capital | $1.39B | $950.2M | $965.3M | $632.6M | $590.9M | |
| Invested capital | $1.77B | $1.35B | $1.37B | $1.07B | $1.21B | |
| Return on assets | 9.6% | 17.9% | 16.7% | -8.1% | -2.4% | |
| Operating ROA | 11.1% | 20.1% | 20.2% | -0.3% | 4.9% | |
| Return on tangible assets | 9.9% | 18.6% | 17.3% | -8.6% | -2.6% | |
| Return on equity | 13.3% | 25.1% | 29.6% | -15.2% | -4.3% | |
| Return on invested capital | 10.6% | 22.1% | 25.5% | -0.4% | 5.4% | |
| Return on capital employed | 12.8% | 26.4% | 25.6% | -0.4% | 6.3% | |
| Earnings yield | 5.2% | 7.7% | 7.7% | -3.7% | -1.3% | |
| Free cash flow yield | 10.4% | 8.5% | 7.7% | -0.4% | 1.9% | |
| Capex / Op. cash flow | 7.8% | 7.6% | 12.0% | 181.8% | 28.5% | |
| Capex / Depreciation | 148.8% | 117.4% | 64.1% | 49.1% | 36.9% | |
| Capex / Sales | 2.7% | 2.1% | 2.9% | 3.4% | 2.5% | |
| SG&A / Sales | 48.4% | 41.4% | 41.5% | 53.1% | 46.8% | |
| R&D / Sales | 22.0% | 15.7% | 16.3% | 24.5% | 24.8% | |
| Stock comp / Sales | 6.7% | 6.2% | 6.1% | 8.5% | 7.5% | |
| Intangibles / Total assets | 3.3% | 4.1% | 4.0% | 6.1% | 8.2% | |
| Days sales outstanding | 83d | 91d | 73d | 97d | 102d | |
| Days payables outstanding | 201d | 68d | 95d | 55d | 103d | |
| Operating cycle | 448d | 363d | 342d | 401d | 380d | |
| Cash conversion cycle | 247d | 295d | 247d | 346d | 277d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-3.1%EV / Sales ▼-17.3%EV / EBITDA ▲+17.2%EV / Op. cash flow ▼-3.508Earnings yield ▼-0.025Graham number ▼-1.935
Profitability
Return on equity ▼-0.118Return on assets ▼-0.083Return on invested capital ▼-0.115Return on capital employed ▼-0.137Operating ROA ▼-0.090Income quality ▲+0.959Tax burden ▲+0.002
Efficiency
Days sales outstanding ▼-8.669Days payables outstanding ▲+132.674Operating cycle ▲+84.546Cash conversion cycle ▼-48.128Capex / Sales ▲+0.006R&D / Sales ▲+0.062
Balance-sheet strength
Current ratio ▲+0.507Net debt / EBITDA ▼-2.737Working capital ▲+435568000.000Invested capital ▲+422615000.000Intangibles / Total assets ▼-0.008
Change over 5 years
Valuation
Market cap ▲+23.1%EV / Sales ▼-26.0%EV / EBITDA ▼-50.0%EV / Op. cash flow ▼-30.744Earnings yield ▲+0.065
Profitability
Return on equity ▲+0.176Return on assets ▲+0.119Return on invested capital ▲+0.051Return on capital employed ▲+0.065Operating ROA ▲+0.062Income quality ▲+4.266Tax burden ▲+1.378
Efficiency
Days sales outstanding ▼-18.942Days payables outstanding ▲+97.491Operating cycle ▲+68.287Cash conversion cycle ▼-29.205Capex / Sales ▲+0.003R&D / Sales ▼-0.028
Balance-sheet strength
Current ratio ▲+1.296Net debt / EBITDA ▼-3.615Working capital ▲+794841000.000Invested capital ▲+554017000.000Intangibles / Total assets ▼-0.049
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-03 Alkermes plc $ALKS Shares Sold by Glenmede Trust Co. NA Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 378,090 shares of the company''s stock after selling 34,830 shares during the period. Glenmede Trust Co. NA owned about
- 2026-07-28 Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
- 2026-07-28 Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
- 2026-07-28 Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-07-28 Alkermes Q2 Earnings Call Highlights Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company''s acquisition of Avadel. The company also highlighted progress across its orexin development pipeline and reiterated most of its full-year financial outlook.
- 2026-07-28 Alkermes (ALKS) Reports Break-Even Earnings for Q2 Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago.
- 2026-07-28 Alkermes plc Reports Second Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company''s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast ma.
- 2026-07-21 Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-14 Alkermes to Report Second Quarter Financial Results on July 28, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company''s second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes'' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast.
- 2026-07-13 Alkermes'' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim.